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In this review, current knowledge of hormones impact on prostate, breast and endometrium cancer growth and transition to hormone 
therapy resistant phenotype is summarized. A special consideration is given to genetic alterations and hormone responsive signa ling 
pathways. Estrogen, androgen and progesterone are the key drivers in these cancer variants. Hormone receptors and their interplay 
with plenty of growth factors generated by the tumor microenvironment contribute greatly to carcinogenesis and cancer cell pro-
liferation. The tumor cell plasticity that could explain a loss of responsiveness to hormone deprivation therapy and aggressive course 
of the diseases has been addressed.
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GENERAL ISSUES
The hormones are known as all-round regulators 
of the cell growth, maturation and differentiation, 
as well function and metabolism. Their impact on tu-
mor growth and progression can be direct or indirect. 
Some normal and malignant tissues demonstrate 
almost absolute dependence of growth upon steroid 
hormones. The issue of the initiating role of the an-
drogens and estrogens in cancerous transformation 
of the prostatic, endometrial, breast and ovarian 
epithelium is still under discussion. In the meantime, 
there are no doubts of their direct promotional effect 
on these tumors growth and progression. An obvious 
example of indirect effect is an increased tumorigenic 
risk in chronic stress owing suppressive influence 
of adrenal corticosteroids on the immune system.
Coincidence of the response of normal and car-
cinoma’s tissues to steroid hormones has created 
a basis of successful hormonal therapy of prostate, en-
dometrium and breast cancers. As regards to the pros-
tate cancer (PCa), it was started with the remarkable 
milestone work by C. Huggins and C.V. Hodges [1]. 
In fact, this work was underlied by animal research 
discovery of postcastration atrophy of prostatic 
epithelium and impressive data on absence of PCa 
in the men who have been orchidectomized in child-
hood or adolescence.
All the three above-mentioned tumors emerge 
and develop like any others of different localization. 
However, it must be pointed that they mainly belong 
to hormone-dependent type, which determines their 
uniqueness and specificity.
Steroid-dependent tumors cluster is characterized 
by a few common features as following:
1. The tumors are originated from epithelium layer, 
and most often identified by pathologist as carcinoma.
2. Hormones do not play essential role in initiation 
of carcinogenesis.
3. Deviations in hormone receptor and other sig-
naling pathways seem to be of a great importance 
in initiating the tumor growth.
4. Because of mutations and chromosomal abnor-
malities, there are established links between steroid 
hormones and expression of oncogenic transcriptional 
factors. For this reason, steroids exert powerful effect 
on the cancer cells proliferation and promote the tumor 
progression.
5. BRCA1 seems to be involved into androgen 
and estrogen receptors signaling, so its mutations 
or deletion might apply to tumorigenesis and growth 
of prostate, breast and ovarian cancers.
6. In the prostate, the mammary gland and endo-
metrium, steroid hormones delegate many of their 
functions to local growth factors (EGF, FGF, NGF, VEGF, 
IGF-1, PDGF, and TGF). This indicates an importance 
of epithelial-stromal interrelationship in pathogenesis 
of hormone-dependent cancers.
7. Hormone deprivation therapy is successfully 
used for palliative treatment of prostate, breast and 
endometrium cancers and their metastasis.
8. Signaling rearrangements and changes 
in the rate of hormone-dependent and hormone-
independent cells inside tumor that occur during 
steroid hormone deprivation therapy usually lead 
to prevalence of hormone-independent cell type and 
therefore to resistance to this kind of treatment.
Whether colorectal cancer is a kind of estrogen-
dependent tumor remains unclear.
PROSTATE CANCER
PCa is known as the most commonly diagnosed 
cancer and the second leading cause of death related 
to malignant tumors in male population of developed 
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countries. In Ukraine, amount of PCa cases increased 
2.4-fold since year 1991 till 2009, and the same rise 
was observed between 2005 and 2012. In 2013–2014, 
PCa was the third malignancy in the Ukrainian male 
population preceeded by respiratory organs and non-
melanoma skin cancers, and occupied the first place 
in the list of oncourology diseases [2].
In 80–85% of PCa (adenocarcinoma) cases, 
patients positively respond to androgen deprivation 
therapy (ADT). The crucial role of androgen steroids 
in PCa growth and progression is generally appreciated 
and confirmed by an increasing of experimental and 
clinical evidence. The tumor growth and dissemination 
can be retarded by orchidectomy or other ADT mo-
dalities including administration of androgen receptor 
(AR) antagonists, hypothalamic gonadoliberin (LH-RH) 
agonists and antagonists, estrogens, and inhibitors 
of steroid 5α-reductase. These methods are aimed 
at suppression of testicular testosterone synthesis, 
metabolism or testicular and adrenocortical androgen 
activities.
In many PCa cases, efficacy of ADT is not such 
high as one expects. The attempts to find out cor-
relation between blood serum testosterone levels 
and an incidence of PCa or the results of ADT failed. 
Nevertheless, many investigators have noticed 
an association of increased PCa risk and an increase 
in serum testosterone concentrations and a decrease 
in sex hormone binding globulin (SHBG) [3, 4], while 
the others were unable to confirm this [5, 6]. According 
to collaborative analysis of 18 worldwide prospective 
studies that included 3886 men with incident PCa and 
6438 control subjects serum concentrations of sex 
hormones (total testosterone, calculated free testos-
terone, 5α-dihydrotestosterone (DHT), dehydroepian-
drosterone sulfate, androstenedione, androstanediol 
glucuronide, estradiol and calculated free estradiol) 
were not associated with the risk of PCa [4].
The results of our studies are in accordance with 
the reports on elevated testosterone in advanced and 
metastatic stages of the disease. There was a gain 
in SHBG levels in PCa patients with advanced disease 
when compared to those of healthy human males 
of comparable age [7] that corresponds to the data 
of other authors [4, 8].
Being mainly the “privilege” of aging men the risk 
of developing PCa might be associated with a low 
serum testosterone (< 8–12 nmol/l). Before radical 
prostatectomy, there was found a nonlinear U-shaped 
association of total preoperative testosterone and its 
correlation to estradiol with high-risk PCa, so both 
the lowest and highest values of those parameters 
has achieved independent predictor status for a high-
risk PCa [9]. Japanese authors reported an absence 
of a linkage between testosterone, SHBG levels 
and a risk of developing PCa [6]. However, a variant 
in SHBG gene seems to implicate in prostate carcino-
genesis, because SHBG D356N heterozygotes have 
about 34% higher risk of PCa among white popula-
tion [10]. In prospective collaborative study, no clear 
impact of the serum total, free testosterone and other 
androgens as well as estrogens on PCa risk has been 
estimated [4].
Few studies supported an association between 
low testosterone in aging men and an increased risk 
of PCa, high Gleason scores, aggressive behavior 
of the disease and worse survival [11–14]. What 
the  aging hypogonadic men are more prone to de-
velop PCa is not proved yet anyway. Should this hypo-
thesis be true, a current knowledge on cellular and 
molecular mechanisms of prostatic carcinogenesis 
could unfold this paradox. At least, two explanations 
seem to be convincing enough to support this point 
of view as following:
1. Even low androgen concentrations are able 
to promote intraepithelial stem cell proliferation and, 
in some cases, an initial differentiation to oncogenic 
phenotype [15], perhaps due to fusion of oncogene 
encoding androgen-dependent transcription factor 
ERG to 5-untranslated region of transmembrane 
protease serine (TMPRSS2) gene [16–18].
2. In the prostate physiology, testosterone and its 
active metabolite, DHT, directly stimulate a late ter-
minal stage of acinar epithelium differentiation and 
secretory function. The same effect one can observe 
in cultured LnCaP cells which are widely used as andro-
gen-sensitive PCa in vitro model, that is without growth 
factors produced by stromal elements. Presumably, 
in a case of low serum testosterone concentration, 
some transient or intermediate luminal epithelial cells 
generated from stem cells in adult prostate might 
remain undifferentiated and thereby involved in ma-
lignant transformation [15]. As a tumor starts to grow, 
it becomes sensitive to proliferative effect of testoste-
rone and suppressive effect of ADT until transforming 
to ADT-resistant phenotype.
All those facts means that testosterone replace-
ment therapy in aging men having low serum tes-
tosterone should promote terminal differentiation 
of prostatic epithelium without an increase of PCa 
risk. Indeed, clinical follow-up observations did not 
demonstrate such a complication despite appreci-
ated fact on the presence of small sleeping tumors 
in the prostate of elderly men [19–21]. In general white 
population, these occult tumors are incidental findings 
by pathologist on post-mortal section in 12% of sud-
denly died organ donors starting from the 4th decade 
of life [22].
Some PCa patients demonstrate aggressive tumor 
growth and progression, but other ones, especially 
elderly men, do not. There is a point of view, that PCa 
which affects an elderly man is a biological pheno-
menon of senescence [23]. The authors postulate 
that it depends on the proteins involved in control 
of regenerative potential, and late-life low-grade PCa 
which is characterized by indolent clinical course 
should be considered as a special PCa subcategory.
In summary, androgens could promote pre-existing 
PCa growth, but with long period of time before clini-
cally manifested. There is no strong evidence of corre-
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lation between endogenous or exogenous androgens 
and PCa incidence, and further research is required.
Various chromosomal, mutational deviations and 
epigenetic modifications associated with PCa risk 
and the tumor have been described including muta-
tions of CDKN1B, MCM7, IL11RA, HMGN1, the lost 
of heterozygosis at 8h22 locus, silencing of expression 
of TP53 gene, abnormal methylation in high-density 
C-G dinucleotide sequences regions of DNA, GSTP1, 
Laminin-5 genes and expression of CDKN2 gene 
which participates in the cell cycle control, and many 
others. CAG and GGC repeat length polymorphism 
in AR molecule is associated with a risk for PCa [24]. 
In the meantime, some authors could not confirm this 
for CAG repeats [5].
Multiple PCa risk variants were discovered on chro-
mosome 8q24. In many advanced and metastatic PCa 
cases, changes of expression of RAS, MYC, BCL2 on-
cogenes and the genes encoding numerous growth 
factors were found. Also some other alterations occur 
such as hyperactivity of IKB5A1 and IKB5A2 genes 
encoding two isoenzimes of steroid 5-alpha-reduc-
tase which converts testosterone to DHT. It has been 
shown that hyperexpression of antiapoptotic gene 
TRPM2 commonly found in androgen-dependent 
tumor Shionogi is closely associated with its progres-
sion [25]. This gene is responsible for active cell death 
via apoptosis, and normally is repressed by androgens. 
Its overexpression leads to the loss of apoptotic po-
tential. Recently a significant association between 
NUDT10 rs5945572 polymorphism and PCa risk was 
confirmed in a meta-analysis [26].
In accordance with a multifactorial hypothesis 
of prostate carcinogenesis [24], androgens augment 
the carcinogenic potention of endogenous or envi-
ronmental carcinogens, such as some estrogen me-
tabolites, reactive oxygen species, diet and genetic 
determinants.
It is commonly recognized that AR, P13K/AKT and 
PTEN signaling pathways are directly involved in PCa 
progression. In majority of primary PCa cases (ap-
proximately 80%), androgens promote proliferation 
and inhibit apoptosis of the tumor epithelium cells 
like they do in normal prostate tissue. AR-mediated 
mechanism activates prostate-specific antigen (PSA) 
gene expression and, correspondingly, PSA produc-
tion by acinar epithelium [27]. For many years the se-
rum levels of total and free PSA are widely being used 
as a main biochemical markers for PCa diagnosis and 
control of its progression. Testosterone promotes an-
giogenesis due to enhancement of VEGF production. 
We observed angiogenesis in the prostate ventral lobe 
of castrated immature rats after testosterone replace-
ment treatment [28].
It becomes evident from experimental studies 
in animal models that estrogens potentiate androgen-
dependent PCa development and progression [29]. 
Estrogens originate from fat and presumably from 
PCa tissue through conversion of testosterone and 
androstendione with participation of the aromatase 
enzyme complex. Estrogen promoting effect is realized 
through estrogen receptor-alpha (ERα). High levels 
of this receptor type were found in hormone-refractory 
PCa as well as in the lymph nodes and metastasis.
The key role in androgen activities belongs 
to the AR signaling. That is why androgen ablation 
as surgical castration and combination treatment 
with LH-RH agonists and AR antagonists which inhibit 
both testicular and adrenal androgens at the receptor 
level (maximum androgen blockade) are appreciated 
as effective palliative therapeutic modalities in terms 
of survival and quality of life in the patients with ad-
vanced or metastatic PCa. Alternatively, a low-dose 
estrogen-antiandrogen therapy can be used [7]
In the blood, testosterone is bound princi-
pally to SHBG and in less degree to albumin. About 
2.5–3.0% of circulating testosterone is free and 
able to enter the cell, where it almost completely 
(about 90%) irreversibly converted to DHT due 
to 5α-reductase activity. This enzyme is distrib-
uted in the prostate epithelium and stromal cells. 
Type 1 5α-reductase is localized mostly in the glan-
dular epithelium, while type 2 prevails in the stroma.
According to F. Labrie’s “intracrinology” concept, 
a significant portion of the human and primate pros-
tate DHT originates from inactive or weak androgens 
(DEAS, androstenedione) produced by the adrenal 
cortex [30, 31]. PCa is associated with empowered 
conversion of androstenedione to testosterone [32]. 
De novo synthesis of androgens in PCa tissue is ca-
pable of activating AR signaling program even in cas-
trate-resistant stage of the tumor progression [33, 34].
The next intracellular events are similar for all ste-
roid hormones. DHT binding to the prostatic cytoplasm 
AR that is coupled with heat-shock proteins is the first 
step of androgen signal transduction from receptor 
to effectors. Cytoplasm AR belongs to a superfami-
ly of ligand-dependent transcriptional factors. DHT 
binding leads to dissociation of heat-shock proteins 
from the receptor, its phosphorilation, conformational 
modifications and dimerization. After translocation 
of the hormone-receptor complex into nucleus, DHT 
binds to the DNA androgen-responsive nucleotide 
sequences located within the promoters of androgen-
responsive genes. In this case, DHT acts as a delivery 
tool for AR. This allows AR dimer in co-operation 
with other transcriptional factors and co-activators 
or co-repressors to regulate gene activity. Intratumoral 
testosterone which did not undergo 5α reduction and 
represents a minor portion of prostatic androgens also 
is capable of binding AR though with less affinity than 
that of DHT. Hopefully, selective targeting the DNA-
binding domain of AR represents a new approach 
to treatment of PCa [35].
Content of AR in PCa and its metastasis is extremely 
variable and obviously can not be used for prognosis 
and drug therapy selection. In many cases of low-
differentiated PCa, it could not be found at all. In our 
study [7], no correlations between concentrations 
of cytoplasmic AR in the human PCa tissue and a stage 
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of the disease or PSA levels were found out. This is not 
surprising because of heterogeneity of the tumor tis-
sue composition. High variability of the epithelial and 
stromal ratio in PCa tissue samples that have been ta-
ken from the patients undergone radical prostat ectomy 
contributes greatly to the results. It must be also taken 
into account that beside of a cytoplasmic AR there is its 
constitutive nuclear form, so some part of androgens 
can interact with it omitting cytoplasm receptor.
Intracellular AR signal pathways in PCa tissues 
dramatically change during the tumor progres-
sion [36–38]. PCa progression leads to androgen-
independent state. Eventually PCa patients do not re-
sponse to hormonal therapy (ADT) anymore. However, 
the tumor preserves ability to grow in presence of even 
extremely low levels of testosterone in its environment, 
for instance, after bilateral orchidectomy. Therefore, 
the terms “androgen-independent” or “androgen-
refractory” does not mean absolute inability of PCa 
to be stimulated with androgen steroids of testicular 
or the adrenal cortex origin, it rather means resistance 
to hormonal therapy. Due to genetic and epigenetic 
adaptations, PCa remains sensitive to AR mediated 
growth signaling that support malignant cells surviving 
even after androgen ablation. However, high-grade 
advanced and metastatic PCa (G4) shows an attenu-
ated androgen signaling protein and gene signature, 
based on study of 101 cell populations isolated with 
micro-dissection [39].
It must be taken into consideration that the tumor 
resistance to ADT can be caused by the membrane 
p-glycoprotein mediated drug efflux, and substitution 
of an antiandrogen for another one sometime resume 
therapeutic efficacy of androgen blockade.
The changes of expression of a number of AR co-
regulators (ARA 54, ARA 55, ARA 70, IL-6, ART 27, 
Her2/neu) were found in PCa cells and may influence 
on transcriptional activity of AR [40]. It has been shown 
that calcium ion signaling contributes to transition 
of LNCaP cells to androgen-insensitive, apoptosis-
resistant neuroendocrine phenotype [41, 42].
In a few PCa-derived cell lines, insulin promoted 
mitogenic activity directly through insulin receptor 
without participation of IGF-1 receptor [43]. In ad-
vanced stage of PCa growth, IGF-1 and other peptide 
growth factors (EGF, TGF-α, TGF-β, FGFb) may acti-
vate the mutant AR more efficiently then the wild-type 
receptor [44].
Amplification of AR gene in human PCa biopsies 
was described in 28% of patients who relapsed after 
endocrine therapy [45]. In all cases but one, the gene 
structure was normal. What is noticeable is that survival 
of patients with the gene amplification was significantly 
greater in comparison with those who did not demon-
strate this phenomenon. Perhaps the longer AR sig-
naling persists, the more possibility exists to support 
androgen-induced normal differentiation of the stem 
cells in the prostate.
To keep PCa cells in differentiated and ADT-
responsible state as long as possible, the optimal 
androgen deprivation concept alternatively to maximal 
androgen blockade seems justified [46]. This ap-
proach includes combining therapeutics simultane-
ously targeting different mechanisms of PCa growth 
and progress, drug dosage reduction for decreasing 
cardiovascular and other complications, intermittent 
endocrine therapy with monitoring blood PSA levels, 
withdrawal treatment when remission was achieved, 
and replacement antiandrogen for another one 
in relapse. Similar strategy was recently proposed for 
treatment of castration-resistant PCa [47].
In animal research, we have studied an efficacy 
of combined drug treatments which interfere with 
different regulatory mechanisms of testosterone 
synthesis, metabolism and its action towards nor-
mal rat prostate and transplanted human neoplastic 
prostate tissues [7, 28, 48–51]. There were studied 
various dosage protocols and the combinations 
of nonsteroidal antiandrogen (flutamide), estrogens 
(diethylstilbestrol, hexestrol, chlorotrianizene, hon-
van), steroid 5α-reductase inhibitor (finasterid), LH re-
leasing hormone (surfagon), recombinant cytokine 
EMAP II, etc. Pharmacodinamic effects were evaluated 
as characterized by axessory sexual glands morpho-
logy, DNA, RNA, protein and other ingredients synthe-
sis and contents. Based on the results of the studies, 
a low dose estrogen-antiandrogen therapy has been 
implemented in clinical practice [7].
The role of AR amplification in pathogenesis and 
clinical course of PCa is still being discussed [40, 52, 
53]. Perhaps, this mechanism underlies capability 
of the tumor growth and progression to be stimulated 
by very low amount of androgens in the cells micro-
environment.
PCa genome profiling shows a lot of different so-
matic mutations [54]. The authors suggest that they 
might determine so-called “endocrine-independent” 
PCa sensitivity to glucocorticoids, progestins and 
even to a new antiandrogen in “antiandrogen with-
drawal syndrome”. Glucocorticoid receptor pathway 
contributes to DHT-induced proliferation of castration-
resistant PCa cells [55]. Though one nucleotide muta-
tions of AR gene in PCa tissue are seldom found, they 
might contribute to the tumor progression and ADT 
refractoriness. Besides, the role of MATE trans porters 
family has to be taken into account as one of the im-
portant mechanisms of drug resistance.
Cross-talk between AR and stromal growth factors 
signaling is of a key importance in normal prostate 
development and in pathogenesis of PCa [56]. It in-
volves control of the cell differentiation, mitosis and 
programmed cell death (apoptosis). Androgen-growth 
factors interactions are disordered in androgen-inde-
pendent PCa and cause sensitization of cancerous 
cells to low level of androgens in their microenviron-
ment. It was shown that progesterone receptor (PR) 
signaling plays an active role in changing PCa-as-
sociated stromal cell phenotype during the disease 
progression [57].
166 Experimental Oncology 37, 162–172, 2015 (September)
In non-malignant prostate and localized PCa, an-
drogens stimulate acinar proliferation through stroma-
originated growth factors. Transition to androgen-
independent state involves hyperexpression of stromal 
growth factors and unusual ability of cancerous epi-
thelial cells to produce EGF, IGF-1, FGFb and some 
other peptides (the epithelium self-stimulation) as well 
as other ligand-independent mechanisms, such 
as cAMP, proteinkinases, and modulation of androgen-
mediated pathways including steroid biosynthesis and 
disregulated metabolism, amplification and mutation 
of AR gene so on [58]. In other words, normal paracrine 
mechanism of prostate epithelium control switches 
to autocrine stimulation.
In a few PCa cell lines, insulin enchanced mitogenic 
activity directly via insulin receptor with no IGF-1 recep-
tor to be involved [43]. In advanced PCa, IGF-1 and 
other growth factors (EGF, TGFα, TGFβ, FGFβ) may 
stimulate mutant AR even more potent than normal 
AR [44].
An increasing number of evidence indicates that 
similarly to other malignant neoplasms there is a link-
age between inflammation and PCa development and 
progression [59]. Chronic inflammation causes prolif-
erative inflammatory atrophy. Among variety of the in-
flammation mediators, interleukines (IL)-6 and IL-8 are 
of importance [40, 60, 61]. In two studied androgen-
dependent PCa cell lines, LNCaP and 22Rv1, IL-8 drove 
cancerous cells to androgen-independent proliferation 
through expression and activation of AR. This might 
be one of the mechanisms of developing ADT refractory 
state because IL-8 promoted neuroendocine differen-
tiation of PCa cells that is an early marker of transition 
to androgen-independent state.
It can not be excluded that in case of artificial an-
drogen deprivation (ADT) androgen-dependent cells 
disappear through apoptosis, and are substituted with 
androgen-independent cell clones [62]. However, re-
cent research results do not confirm this theory. Clonal 
progression of human PCa from Gleason grade 3 (G3) 
to grade 4 (G4) was studied in radical prostatectomy 
specimens using laser-captured microdissected tu-
mors [63]. The TMPRSS:ERG gene fusion confirming 
common clonal origin has been found in all specimens 
studied. Some other genetic and epigenetic features 
proved that a subset of G3 (low-grade PCa) progress 
to G4 (advanced PCa) or they emerge from a common 
precursor. The TMPRSS:ERG gene fusion is a feature 
of aggressive androgen-independent PCa, its ex-
pression can be regulated by a novel ER-dependent 
mechanism [64]. Whether PCa progression is rather 
a result of the tumor genetic and epigenetic adaptation 
than that of clonal selection is still not clear. It seems 
that ADT promotes the emergence of heterogeneous 
PCa cell populations that determine aggressive course 
of the disease [65].
BREAST CANCER
Breast cancer (BCa) is acknowledged as a leading 
cause of death of women at the age of 40–55 years. 
It is soundly believed that an increased disease oc-
currence is facilitated by age-related endocrine rear-
rangements. Breast epithelium hyperplasia increases 
4–9 times a risk of BCa and even more in a case of BCa 
family history. Risk factors include obesity (fat tissue 
produces estrogens and other hormones, as well 
as numerous growth factors and cytokines), ionizing 
radiation, environmental pollution with xenoestro-
gens, alcohol abuse, smoking, menopausal hormone 
replacement therapy, so on. High blood serum levels 
of estrone sulfate, prolactin and testosterone might 
be the predictors of BCa risk [66].
BCa originates from non-differentiated ductal epi-
thelium (85% cases) or lobule type 1 epithelium (15% 
cases), which prevail in nonparous women. In parous 
women, mammary gland epithelium is more diffe-
rentiated (lobules type 3 or 4), therefore they are less 
predisposed to BCa development. Early menarche, 
infertility, late first pregnancy (after age of 35 years) 
increase a chance of the disease.
During puberty, ovarian cycles and pregnancy 
a large number of mammary stem cells undergoes 
differentiation in order to generate new tissue struc-
tures. This process is regulated by systemic hormones 
and locally produced paracrine peptides. According 
to the model proposed by C. Brisken and S. Duss [67], 
“repeated hormone stimulation of stem cells and their 
niches in the course of menstrual cycles may be an im-
portant early event in breast carcinogenesis and may 
explain the conundrum why BCa risk increases with 
the number of menstrual cycles experienced prior 
to a first pregnancy”.
Numerous genetic damages were found in BCa 
cells and considered as markers of the disease: 
deletions of 8p, 11q, 13q, 14q chromosomal re-
gions, elongation of 6q22, 8q22, 11q13, 17q22–24, 
20q13, mutations of BRCA1 and BRCA2 genes, and 
overexpression of ErbB2. Special attention should 
be given to aberrant variants of Foxp3 gene, which 
acts as suppressor of the oncogene HER-2/ErbB2. 
In a huge genome-wide association analysis covering 
about 120 000 BCa cases, SETBP1 at 18q12.3 and 
RNF115 and PDZK1 at 1q21.1 were identified as main 
susceptibility loci for BCa [68].
BCa susceptibility gene BRCA1 is located on chro-
mosome 17q21. It encodes an 1863 amino acid protein 
that is important for normal embryonic development, 
DNA repair, cell proliferation, inhibition of apoptosis, 
maintenance of the genome stability, steroid hormone 
receptor signaling and tumor growth suppression. 
BRCA2 protein performs the same functions. Both 
genes inactivating mutations are predictors of heredi-
tary early onset BCa which occurs in 5–10% of BCa 
cases and breast-ovarian cancer syndrome. Nearly 
half of women bearing these genes mutations develop 
BCa before age of 70 [67, 69].
Remarkable role of BRCA1 protein in pathogenesis 
of hormone-responsive cancers is determined by its 
linkage with sex steroid receptors. BRCA1 inhibits ERα 
activity and activates AR signaling [70, 71].
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It is considered that the local and extraovarian 
(in the fat tissue) biosynthesis of estrogens, especially 
in postmenopausal women, is of a great importance 
as pathophysiological mechanism in development 
of BCa. Obesity is now associated with a low-grade 
inflammation, that via inflammation-induced cytokines 
increases steroid aromatase activity in the breast that 
results in a high local concentration of estrogens. 
Overexpression of CYP19 gene and increased aro-
matase and 17-beta-hydroxysteroid dehydrogenase 
activities are associated with more aggressive course 
of disease [72]. It seems that local catecholestrogens, 
hydroxylated products of estrogen metabolism, con-
tributes to development of BCa.
Normal and malignant mammary epithelium 
grows and functions under multiple hormonal control. 
Numerous stromal paracrine and autocrine growth 
factors as IGF-1, TGFα, TGFβ, EGA, FGF, PDGF and 
other mediate hormonal induction of mammary cells 
proliferation and differentiation, and in tumor progres-
sion [73, 74]. In addition, adipocytes presenting in BCa 
microenvironment generate numerous endocrine, 
inflammatory and angiogenic substances that promote 
tumor growth. For instance, locally produced leptin 
induces androgen conversion to estrogens, which 
is important for BCa tumorigenesis [75].
For many years possible role of thyroid hormones 
as risk factors for BCa was being under discussion. Re-
cently there were published the results of unique pro-
spective study, in which 2185 women were observed 
during at average of 23.3 years. A positive correlation 
between pre-diagnosis blood plasma triiodothyronine 
levels and development of aggressive BCa, metastasis 
and the tumor negative ER and PR phenotypes has 
been revealed [76].
Since G.T. Beatson [77] had estimated the link 
between ovarian secretion and BCa, majority of re-
search was focused on the role of estrogens in its de-
velopment and progression. Amongst plenty of other 
hormones, estrogens demonstrate the most apparent 
mitogenic potency. They play crucial role in normal 
breast development and carcinogenesis as permissive 
agents for carcinogens and tumor growth enhancers.
True role of estrogens in BCa growth and progress 
is controversial and not fully elucidated till now. They 
stimulate proliferation of ductal epithelial cells, but 
promote their differentiation and apoptosis, and inter-
fere with metastatic dissemination due to an increase 
of cell adhesion. In the meantime, ovarian hormones 
promote malignant transformation of breast stem cells 
followed by disease reccurence and metastasis [78].
In the famous Women’s Health Initiative study and 
similar research [79], menopausal women ta king 
estrogen-progesterone replacement therapy had in-
creased incidence of BCa during follow-up period. This 
was not a case of taking estrogen alone in the group 
of women with hysterectomies, and BCa incidence risk 
was even reduced. However, according to a number 
of prospective studies, there is the strongest correla-
tion between higher total and free circulating estradiol 
levels and risk of BCa development in postmeno-
pausal women, and some positive correlation was 
found in premenopausal subjects [80]. Surprisingly, 
in the European Prospective Investigation into Can-
cer and Nutrition with cohort of 801 BCa cases and 
1132 matched control subjects, the higher premeno-
pausal blood plasma testosterone levels were strongly 
related to an increased BCa risk, although a possible 
morbidity increase was found with higher estradiol 
levels in BCa affected women under age 50 [81].
Biological effects of estrogens are mediated by two 
subtypes of estrogen receptors, ERα and ERβ, which 
belong to superfamily of nuclear transcription factors. 
These isoforms mediate direct effect of estrogens 
on proliferation of epithelium and induction of synthe-
sis of stromal growth factors. In particular, estrogens 
promote revascularization of the tumor by increasing 
VEGF production through transcriptional activa-
tion [82]. Recent research identified URB5, an ubiqui-
tin ligase and known oncogene, as an agent targeting 
ERα levels and signaling, and modulating estrogen 
impact on BCa cells proliferation [83].
Likely to other steroid hormones, binding of estro-
gen to cytosolic ER leads to detachment of heat shock 
proteins, phosphorilation and dimerization of ER, fol-
lowed by translocation to the nucleus. The dynamic 
structure of ER is studied in detail [84]. ER binds to es-
trogen responsive element of DNA as ligand-induced 
homodimer and regulates transcription in conjunction 
with co-activators, co-repressors and modulators. 
Transactivation domens, AF1 and AF2, are involved 
in regulation of transcriptional activity of ER. Carboxy 
terminal domain F modulates gene transcription.
In most cases of hormone-responsible BCa (about 
75%), ERα expression is present, whereas ERβ expres-
sion is decreased in comparison with normal tissue. 
There is a suggestion that ERβ exerts a differential 
effect on cell proliferation as compared with ERα 
and might counteract to proliferative ERα signaling 
in the tumor which is associated with tumor progres-
sion [85]. It must be noted, that only about 40% of BCa 
patients respond positively to antiestrogen therapy 
despite the presence of ER.
Along with ER, PR expression in BCa tissue can 
be found in 65% of cases that is indicative of sensi-
tivity to antiestrogen therapy, because PR synthesis 
depends on active ER. In 25% of patients, mostly those 
younger than 40 years, both ER and PR are not found 
that correlates with refractoriness to hormonal therapy, 
aggressive course of disease and poor prognosis.
Progesterone is involved in proliferation of the breast 
normal and malignant alveolar epithelium in the bre-
ast lobules. In these tissues, it stimulates luminal 
progenitor and stem cell population [86, 87]. What 
is surprising is that mammary stem cells respond 
to steroid signaling, despite absence of the PR and 
ER [88]. Progesterone effects are mediated by two 
PR isoforms, A and B, which are coded by one gene 
and normally present in approximately equal amount 
in luminal epithelium. In nondifferentiated BCa, con-
168 Experimental Oncology 37, 162–172, 2015 (September)
tent of the subtype A prevails, that usually can be found 
at early stage of the disease and is indicative of poor 
prognosis. Increased activity of the epidermal growth 
factor and methylation of ER gene promoter is being 
found in a case of PR absence. Conversely, normal rate 
of subtypes A and B correlates with more differentiated 
tumor, and predicts latent course of the disease.
PR seems to play a dual role in regulation of BCa 
growth depending on PR isoforms signaling followed 
by stimulation or inhibition of cell proliferation [89]. 
In the breast basal-like PR-negative non-cancerous 
cells that have been exposed to ionizing radiation, pro-
gesterone generated cancer stem cells via membrane 
PR [90]. It was demonstrated recently that progeste-
rone metabolite, 5α-dihydroprogesterone, stimulates 
mammary carcinogenesis, and this effect can be at-
tenuated with steroid 5α-inhibitor, finasteride [91].
What is intriguing, AR expression in BCa tissue 
is usually found. However, the role of AR signaling 
in pathogenesis of BCa is not fully understood.
Aberrant cross-talk between steroid receptors and 
growth factors signaling is a key mechanism of BCa 
progression to hormone-independent growth. It makes 
the tumor non-responsible to antiestrogen treatment. 
Mutant ER is a frequent finding in hormone-resistant 
BCa [92]. Overexpression of epidermal growth factor 
receptor HER2/neu is of an importance. For example, 
resistance of BCa patients to tamoxifen, steroid 
ER modulator, which exhibits suppressive effect 
on growth of malignant breast epithelial cells due its 
antiestrogenic activity in this organ (but not in uterus), 
is associated with BCa tissue high levels of both HER2/
neu and ER [93]. Some cytoplasmic proteins, like 
vimentin and Notch, can be considered important 
indicators of BCa progression [94].
Recently a possible role of intracellular ferritin 
as a protein promoting growth of BCa has been de-
monstrated. In a few BCa cell lines, ferritin expression 
positively correlated with proliferative activity [95].
ENDOMETRIAL CANCER
The most common histopathological variant 
of endometrial cancer (ECa) is differentiated adeno-
carcinoma. ECa develops mainly in postmenopausal 
age with an average of 61 years. At this period of life 
the ovaries do not ovulate, and because of absence 
of postovulatory luteal bodies progesterone produc-
tion decreases significantly and sometimes can not op-
pose effectively to proliferative influence of estrogens 
despite low estrogen levels. The most important risk 
factors are as following: atypical endometrial hyper-
plasia, early menarche, late menopause, high estrogen 
levels, overweight, nulliparity, family history, diabetes 
mellitus, estrogen monotherapy, hyperandrogenism, 
polycystic ovary syndrome, alcohol [96]. Hyperpro-
lactinemia and hyperinsulinemia that often accom-
pany polycystic ovary syndrome promote proliferation 
of normal and malignant endometrial surface and 
glandular epithelium. Moreover, expression of growth 
hormone, prolactin and corresponding mRNA in ECa 
tissues promotes tumor growth and indicates poor 
prognosis [97]. In endometrial tissue culture, insulin 
stimulates proliferation of epithelium and carcinoge-
nesis. This effect is mediated by mitogen-activated 
proteinkinases and AKT signaling [98]. In 30–40% 
patients, ECa develops despite postmenopausal 
endometrial atrophy, and typifies low differentiation.
It is well documented that high estradiol levels 
in postmenopausal women predict 2–4 fold higher risk 
of ECa development as compared with low estradiol 
levels while premenopausal women do not demon-
strate such association [99].
Mutations of PTEN and TP53, tumor suppression 
genes, were found in 83% and 20% of ECa cases, 
respectively [100]. Loss of PTEN protein expression 
in endometrial specimens is marked in ECa and atypi-
cal endometrial hyperplasia that precedes its emer-
gence [101]. High expression of cyclooxygenase-2, 
which inhibits apoptosis and stimulates angiogenesis, 
is a common finding in well-differentiated ECa tissues. 
Low-differentiated cancers exhibit overexpression 
of p53 in conjunction with low expression of MDM2 and 
p14ARF [102].
Endometrial epithelium develops and functions un-
der multihormonal control; however, active estrogens 
are the main drivers of endometrial cell proliferation. 
Mitogen-activated protein kinases (MAPK) [103] 
and protein kinase Cα [104] mediate 17β-estradiol-
activated ER signaling in the development and pro-
gression of ECa. Another mechanism of estrogen-
stimulated ECa cells growth is MAPK-mediated 
induction of telomerase activity [105].
It was postulated, that in nuclear ER-positive ECa 
cells proliferation is mediated by both ER-Notch and 
GPR 30-PI3K/AKT signaling, whereas in nuclear 
 ER-negative ECa cells the first signaling pathway is not 
involved in cell proliferation [106].
Interestingly, epithelial cells proliferation is not 
arised in response to 17β-estradiol alone, they need 
to be stimulated with EGF, IGF-1 and other growth fac-
tors. It is widely recognized that significant increase 
in local blood flow and vascular permeability preceed 
estrogen-induced proliferation of endometrial epithe-
lium. R.D. Koos [107] hypothesized that microvascular 
changes lead to penetration of IGF-I and other proteins 
into subepithelial stroma resulted in synergistic with 
ER-signaling proliferative effect. The vascular hyper-
permeability is caused by estrogen-induced VEGF, this 
process involves such transcription factors as ERα and 
hypoxia-inducible factor 1.
The shift of local interconversion between es-
trone and 17β-estradiol in favor of the last one in ECa 
grade 1 biopsies contributes to ERα-positive tumor 
growth [108]. Similarly to BCa, ECa growth can 
be stimulated by leptin produced by local adipocytes. 
It is noticeable that in co-cultivated endometrial 
fibroblasts and Ishikawa human ECa cell line leptin 
promotes carcinoma cell proliferation due to enhance-
ment of aromatase activity followed by an increase 
of estradiol formation [109].
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In addition to ERα and ERβ, a novel G protein-
co upled membrane ER, GPER/GPR30, was found 
to  exert non-genomic effects of estrogens. High 
expression of GPER predicts poor ECa prognosis. 
In ERα-negative Hec50 ECa cells and xenografts, 
it mediates estrogen-activated ERK and PI3K via me-
talloproteinase activation followed by transactivation 
of EGFR that results in enhanced tumor growth [110].
Estrogen-dependent subtype accounts about 75% 
of ECa cases. Progesterone functions as an antagonist 
of estrogens, that is exerts antiproliferative effect due 
to several mechanisms. These mechanisms include 
a decrease of ER amount in tissues, stimulation of es-
trogen sulfotransferase and other estrogen-meta-
bolizing enzymes, and targeting mitogenic signaling. 
For this reason high doses of progestins are in use 
for ECa treatment. Besides, progesterone promotes 
differentiation of endometrial cancerous cells followed 
by metaplasia, atrophy and apoptosis. Progesterone 
signaling starts from its binding to PR that is distributed 
in endometrial epithelium and stroma.
ER presence in ECa tissues was found in 30–50% 
of patients with prevalence of ERα subtype. PR-posi-
tive ECa (approximately 50% of patients) responds 
to progestin therapy, while advanced high grade tu-
mor and hormone refractoriness are associated with 
amplification of HER2/neu gene and overexpression 
of consistent oncoprotein [111, 112].
CONCLUDING REMARKS
Despite substantial progress in understanding 
pathogenesis and advances in early detection and 
treatment, hormone-dependent cancers are still 
one of the leading causes of cancer death around 
the world. PCa, BCa and ECa might be considered 
as specific cluster of the malignant tumors. In many 
cases family history, blood hormone levels and cancer-
related genes predict a high risk of developing PCa, 
BCa and ECa that could be rationale for intent obser-
vation of the corresponding individuals. As regards 
the risk of PCa development, its association with 
age-related low plasma testosterone level still needs 
to be clarified. Basic research of gonadal steroid re-
ceptors signaling and its cross-talk with growth factors 
and cytokines are promising for broadening current 
knowledge of mechanisms of hormone-dependent 
cancerogenesis and the tumor transition to hormone-
refractory phenotype. Deeper insight into metabolic 
changes is of a big importance for that, as well as for 
comprehension of gonadal steroid receptors interplay 
with DNA, microRNA interference with gene expres-
sion and other key issues of development, growth 
and progress of hormone-dependent tumors. Fur-
ther investigations are needed to clarify complicated 
molecular mechanisms of hormonal impact on tumor 
growth and progression in order to considerably im-
prove outcomes of therapy.
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